LOGIC

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

C-reactive protein (CRP) is an acute-phase protein that has long been recognized as a marker of systemic inflammation. CRP measurement can complement a range of diagnostic markers to monitor infection and direct treatment. However, as economic rationalization...

TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials

Data Published in The Lancet on TMC125, an Investigational NNRTIfrom Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from twoongoing Phase 3 studies (DUET-1 and DUET-2) showed significantlymore HIV-1 adult patients with documented non-nucleoside reversetranscriptase inhibitor (NNRTI) and protease inhibitor (PI)resistance reached an undetectable viral load (defined as achievingco...

Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jul 3, 2007 - NymoxPharmaceutical Corporation (NASDAQ: NYMX) today announced thatfurther clinical results from the Company's studies of NX-1207 forbenign prostatic hyperplasia (BPH) will be presented at the NewEngland Section of the American Urological Association Meeting inBoston in September. The paper is authored by leading clinicalresearch inves...

GenoLogics Announces Bioinformatics Partnership with Illumina

GenoLogics Announces Bioinformatics Partnership withIllumina BEYOND GENOME CONFERENCE, San Francisco, CA, June 21, 2007-GenoLogics, a leading developer of lab and data managementsoftware solutions for life sciences research, today announced thatit has penned an agreement with Illumina, Inc. to become atechnology partner and participant in IlluminaConnect, abioinformatics software...

Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study

YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced ViralResearch Corp. (OTCBB: ADVR), a research based biopharmaceuticalcompany, announced today that preliminary findings from its ongoingPhase II dermatological study show topical treatment with AVR118appears to have clinical activity in reducing inflammation andredness associated with surgical incisions or dermatologicdermabrasion....

Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial

GERMANTOWN, Md., June 13, 2007 /PRNewswire-FirstCall/ -- AvalonPharmaceuticals, Inc. , today announced that it is will provide anupdate on the Phase I clinical trial of AVN944 in hematologicmalignancies on Tuesday, June 19, 2007, after the close of the U.S.financial markets. The Company will also host a conference call onWednesday, June 20, 2007 at 8 a.m. Eastern Time. Interestedinvestor...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

HDAC Inhibitor MGCD0103 Demonstrates substantial Response Ratein Two Clinical Trials Clinical Data Presented on Pilot Pharmacokinetic Study of OralAzacitidine Exelixis Reports Integrated Data From Phase II Clinical Trialsof XL999 at ASCO Clinical Data Reported on Vidaza in Hematologic Malignancies andAdva...

Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association

* Ozarelix Effective in Improving Symptoms and Urine Flow, WithLong Lasting Effect in Phase 2 Study IRVINE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- SpectrumPharmaceuticals, Inc., today announced Phase 2 safety and efficacydata for ozarelix, the Company's drug candidate for the treatmentof benign prostatic hypertrophy (BPH), at the American UrologyAssociation Annual Meeting held at...

Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association

-- Median time to pain progression is 66.1 weeks for thesatraplatin arm compared with 22.3 weeks for the placebo arm --Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representinga 36% reduction in the relative risk of pain progression MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-FirstCall/-- PRINCETON, N.J., and BOULDER, Colo. -- GPC Biotech AG andPharmion Corporation today a...

Dendreon Announces Presentation of Data at American Urological Association Annual Meeting

-Data May Support Use of Provenge as Front-line Treatment inAdvanced Prostate Cancer- SEATTLE and ANAHEIM, Calif., May 20, 2007 /PRNewswire-FirstCall/-- Dendreon Corporation today announced the presentation of datafrom an analysis of Phase 3 Studies (D9901 and D9902A) that showeda prolonged survival benefit for patients who were initiallytreated with Provenge (sipuleucel-T) who then went...

Revolutionary Immunologic Data Explains Function of Diamyd Diabetes Vaccine

Diamyd Medical AB (<a target="_blank" href="http://www.omxgroup.com/">www.omxgroup.com ticker: DIAM B; ticker DMYDY) STOCKHOLM, Sweden, May 3, 2007 – During a presentationmade in Linkoping, Sweden at the Sweden-Seattle Diabetes Conferencethis past week-end, Professor Johnny Ludvigsson, the Principal...

EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers

ROCKVILLE, Md., April 19, 2007 /PRNewswire-FirstCall/--EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,today announced the presentation of preclinical results for MKC-1,its novel cell cycle inhibitor. The data were presented by EntreMedscientists at the American Association for Cancer Research (AACR)Ann...

Karmanos Physician-Scientists Examine Racial Disparities in Patients with Gynecologic Cancer

DETROIT, April 16, 2007 /PRNewswire/ -- Karmanos CancerInstitute physician-scientists today reported on two researchstudies investigating racial disparities in patients withgynecologic cancer at the American Association of Cancer Researchannual meeting in Los Angeles, CA. Caucasian patients with endometrial or ovarian cancer, onaverage, live longer than their African American count...

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons

Company Announces Extension of Phase I/IIa Trial to 9 mg DosageLevel HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ --Boston Life Sciences announced today that clinical data on its leadnerve repair therapy, Cethrin(R), were presented in the Neurotraumaand Critical Care Scientific Session at the 75th Annual Meeting ofthe American Association of Neurological Surgeons (AANS) inWash...

Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting

WASHINGTON--(BUSINESS WIRE)--Apr 16, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced an oral presentation of updated datafrom a Phase 1/2 investigator-sponsored trial of the company'sinvestigational cancer vaccine Oncophage(R) (vitespen) inrecurrent, high-grade glioma at the 75th annual meeting of theAmerican Association of Neurological Surgeons (AANS; abstract#606). Preliminary result...

New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders

Data to be Presented April 15th at EASL Conference in Barcelona,Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007/PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developerof drugs for infectious diseases, has received new top-line resultsconfirming the previously announced clinical results (November 6,2006) indicating evidence of clinical benefit, safety andtolerability in a Phas...